BIO-Europe Spring® 2017: Incorporating flexibility into your R&D strategy

March 30, 2017
Strategic decisions made early in clinical development often have an impact on the downstream commercial potential of an asset. This is true for both large pharma and emerging biotech companies. What choices must be made during early clinical development? What are the trade-offs to consider? How do these key decisions affect the commercial potential, partnering opportunities, and ability to invest in other assets in a therapeutic franchise or overall pipeline?
Previous Video
BIO-Europe Spring® 2017: Commercializing cell and gene therapies
BIO-Europe Spring® 2017: Commercializing cell and gene therapies

New business models for clinical development and manufacturing require strategic partnerships among researc...

Next Video
BIO-Europe Spring® 2017: Key considerations in microbiome partnering
BIO-Europe Spring® 2017: Key considerations in microbiome partnering

The human microbiome is garnering research interest across the globe and industry is responding to the grow...